Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marisa Iborra

Showing results (61-70 of 92) with videos related to

Pageof 10
Sort By:
Gastroenterologia Y Hepatologia|February 4, 2024
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative ColitisFrancisco Rodríguez-Moranta, Federico Argüelles-Arias, Joaquín Hinojosa Del Val, et al.
Scientific Reports|October 21, 2020
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patientsMarisa Iborra, Natalia García-Morales, Saoia Rubio, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|March 14, 2020
Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort studyAna Garcia Garcia de Paredes, Enrique Rodriguez de Santiago, Carlos Rodriguez-Escaja, et al.
Journal of Crohn'S & Colitis|August 22, 2024
Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA RegistryMarisa Iborra, Berta Caballol, Alejandro Garrido, et al.
Alimentary Pharmacology & Therapeutics|March 14, 2021
Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-α: results from the ENEIDA registryFrancisco Mesonero, Jesús Castro-Poceiro, Jose M Benítez, et al.
Gastroenterologia Y Hepatologia|December 25, 2017
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patientsManuel Barreiro-de Acosta, Ignacio Marín-Jiménez, Abel Panadero, et al.
Alimentary Pharmacology & Therapeutics|August 10, 2020
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registryMarisa Iborra, Belén Beltrán, Agnes Fernández-Clotet, et al.
Medicina (Kaunas, Lithuania)|December 31, 2025
Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort StudyLuis G Guijarro, Patricia de Castro-Martínez, María Chaparro, et al.
Journal of Gastroenterology|October 11, 2016
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patientsMarisa Iborra, Javier Pérez-Gisbert, Marta Maia Bosca-Watts, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 29, 2026
Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumabPatricia de Castro-Martínez, Luis G Guijarro, Jorge Monserrat, et al.
Pageof 10

Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
Gastroenterologia Y Hepatologia|February 4, 2024
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative ColitisFrancisco Rodríguez-Moranta, Federico Argüelles-Arias, Joaquín Hinojosa Del Val, et al.
Scientific Reports|October 21, 2020
Real-life experience with 4 years of golimumab persistence in ulcerative colitis patientsMarisa Iborra, Natalia García-Morales, Saoia Rubio, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|March 14, 2020
Idiopathic acute pancreatitis in patients with inflammatory bowel disease: A multicenter cohort studyAna Garcia Garcia de Paredes, Enrique Rodriguez de Santiago, Carlos Rodriguez-Escaja, et al.
Journal of Crohn'S & Colitis|August 22, 2024
Subcutaneous Infliximab Cutoff Points in Patients With Inflammatory Bowel Disease: Data From the ENEIDA RegistryMarisa Iborra, Berta Caballol, Alejandro Garrido, et al.
Alimentary Pharmacology & Therapeutics|March 14, 2021
Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-α: results from the ENEIDA registryFrancisco Mesonero, Jesús Castro-Poceiro, Jose M Benítez, et al.
Gastroenterologia Y Hepatologia|December 25, 2017
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patientsManuel Barreiro-de Acosta, Ignacio Marín-Jiménez, Abel Panadero, et al.
Alimentary Pharmacology & Therapeutics|August 10, 2020
Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registryMarisa Iborra, Belén Beltrán, Agnes Fernández-Clotet, et al.
Medicina (Kaunas, Lithuania)|December 31, 2025
Comparative Efficacy and Immunogenicity of Infliximab and Adalimumab in Crohn's Disease: A Prospective Cohort StudyLuis G Guijarro, Patricia de Castro-Martínez, María Chaparro, et al.
Journal of Gastroenterology|October 11, 2016
Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patientsMarisa Iborra, Javier Pérez-Gisbert, Marta Maia Bosca-Watts, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|May 29, 2026
Th1/Th17 cytokine signatures correlate with Crohn's disease activity in a 54‑week cohort of patients treated with adalimumabPatricia de Castro-Martínez, Luis G Guijarro, Jorge Monserrat, et al.
Pageof 10